As homodimers and heterodimers involving EGFR, ERBB2/HER2, and ERBB3/HER3 contribute to oncogenic signaling in in NSCLC3,9,12, and given that some antibodies used on RPPA panels are not optimized13, we further investigated MSI2 control of this ERBB protein family in detail using a panel of NSCLC cell models. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.